So Yeon Kim(@Sokim_33) 's Twitter Profileg
So Yeon Kim

@Sokim_33

Thoracic oncology | Phase I @YaleCancer | @MontefioreNYC alum | @TuftsMedicalCtr alum | @Princeton alum

ID:1303401698237517825

calendar_today08-09-2020 18:36:01

22 Tweets

177 Followers

247 Following

soria(@jsoriamd) 's Twitter Profile Photo

The efficacy of is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in a MHC-I-context. There is new evidence that CD4+ T cells can contribute to antitumour immunity, independent of their role as helpers and regulators…

The efficacy of #immunotherapy is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in a MHC-I-context. There is new evidence that CD4+ T cells can contribute to antitumour immunity, independent of their role as helpers and regulators…
account_circle
Lauren Fishbein(@LMFendo) 's Twitter Profile Photo

About last night. A feast! They had to place a small table behind us for additional food plates which didn’t fit on the table. Amr knows how to welcome the guests to Cleveland!
It’s been fun!
NANETS

About last night. A feast! They had to place a small table behind us for additional food plates which didn’t fit on the table. Amr knows how to welcome the guests to Cleveland! It’s been fun! @NANETS1
account_circle
Yale Cancer Center(@YaleCancer) 's Twitter Profile Photo

An analysis by So Yeon Kim Amin Nassar, MD & colleagues of treatment options for patients with stage III unresectable EGFR mutant showed consolidation EGFR TKI therapy yielded significantly longer disease free survival than durvalumab Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp

An analysis by @Sokim_33 @AminNassarMD & colleagues of treatment options for patients with stage III unresectable EGFR mutant #NSCLC showed consolidation EGFR TKI therapy yielded significantly longer disease free survival than durvalumab #ASCO23 #lcsm @SmilowCancer @YaleMed @YNHH
account_circle
Jarushka Naidoo(@DrJNaidoo) 's Twitter Profile Photo

Is a sea change?

- Ph III neodj durva+chemo + 1yr durva post surgery v chemo alone in early stage NSCLC
- 70% stage III
- EFS HR 0.68, pCR 17% v 4%
- cis or carbo had equiv EFS
- ?females did not do as well for EFS or pCR - more data needed

OncoAlert

#AACR23 Is #AEGEAN a sea change? - Ph III neodj durva+chemo + 1yr durva post surgery v chemo alone in early stage NSCLC - 70% stage III - EFS HR 0.68, pCR 17% v 4% - cis or carbo had equiv EFS - ?females did not do as well for EFS or pCR - more data needed @OncoAlert #LCSM
account_circle
Balazs Halmos(@DrSteveMartin) 's Twitter Profile Photo

2 for the price of..0!
Cambridge Press Elements in Molecular Oncology chapters on precision oncology in NSCLC- EGFR + beyond -available for download for free for 1 wk before paywall comes up
cambridge.org/core/publicati…

2 for the price of..0! Cambridge Press Elements in Molecular Oncology chapters on precision oncology in NSCLC- EGFR + beyond -available for download for free for 1 wk before paywall comes up cambridge.org/core/publicati…
account_circle
Yale Cancer Center(@YaleCancer) 's Twitter Profile Photo

BFAST but be smart! Roy Herbst & So Yeon Kim discuss results of a phase III trial evaluating blood-based tumor mutational burden in patients with treatment-naive advanced-stage in @NatureRevCancer. OncoAlert Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp
nature.com/articles/s4157…

account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Extensive characterization of NSCLC in by Drs. So Yeon Kim Balazs Halmos. Included 21582 samples tested with NGS: METex14 seen in 533 (2.5%). Analysis noted common co-alterations in MDM2, HMGA2, CDK4 more common in MET altered vs wild type.
jtocrr.org/article/S2666-…

account_circle